MissionIR News – VistaGen Therapeutics Awarded U.S. Stem Cell Technology Patent Covering Methods Used to Test Drug Candidates for Liver Toxicity For Liver Stem Cell treatment.
MissionIR would like to highlight VistaGen Therapeutics, Inc. (OTCBB: VSTA), focused on applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of promising drug candidates that have been discontinued during preclinical development ("put on the shelf") due to heart or liver safety concerns.
In the company’s news yesterday, VistaGen Therapeutics announced it has secured a new United States patent covering the company’s proprietary methods used to measure and type the toxic effects produced by drug compounds in liver stem cells.